(This is CNBC Pro’s live coverage of Friday’s analyst calls and Wall Street chatter. Refresh every 20-30 minutes to see the latest posts.) A streaming giant and a company that makes self-driving technology for vehicles were among analysts’ biggest calls Friday. Morgan Stanley raised its price target on Netflix from $600 to $700. Wolfe Research, meanwhile, upgraded Mobileye Global to outperform, forecasting a 30% upside. Check out the latest calls and chats below. All times ET. 6.34am: Novo Nordisk could gain another 30% over the next year, says BMO Capital Markets BMO Capital Markets analyst Evan Seigerman has initiated coverage of leading pharmaceutical company Novo Nordisk with an outperform rating and a price target of $163, which suggests nearly 30% upside for the shares. Novo shares are already up more than 21% this year. “New [is] well positioned to be one of two winners in the obesity market… While other BioPharma players are just entering the obesity landscape, Novo has established itself as a leader following the approval of Wegovy in 2021 (and the approval of Saxenda in 2014),” Seigerman wrote in a Friday note, saying he sees the obesity market growing to be worth more than $130 billion. “The widening of the moat driven by manufacturing, clinical data, patients, diverse pipelines and access supports our bullish view on Novo.” The analyst said his new rating is based on: Novo Nordisk’s numerous obesity and T2D-related development-stage assets that will likely expand the company’s existing portfolio; the company’s expansion of production with Catalent, which it agreed to buy in an effort to increase production of its weight-loss drug Wegovy. This would allow it to continue to supply a “capacity-limited market “, said Seigerman; The company’s significant amount of secondary outcomes data could expand revenue and opportunities in the Medicare market. — Pia Singh 6.19am: UBS upgrades DocuSign, says e-signature stock could have further upside DocuSign shares are now fairly valued, according to UBS. Analyst Karl Keirstead upgraded his rating on the stock from sell to neutral. He increased his price target by $14 to $62, which suggests a potential upside of 4.2% for DocuSign over the next year. This year, the stock is trading just above the flat level. “While we remain on the sidelines given high e-signature market penetration, competition from companies like Adobe, and mixed traction with CLM, we conclude that DocuSign has largely overcome material issues related to post-COVID expansion and has further potential margin upside,” Keirstead wrote in a note Friday. The stock trades at a more reasonable premium to Zoom, the analyst said, adding that its risk/reward ratio now “appears more balanced.” DocuSign’s latest quarter reflects encouraging demand trends, potentially accelerating revenue growth and margin upside, he said. DOCU YTD mountain DOCU year to date — Pia Singh 5.54am: Citi cuts Tesla price target due to near-term demand issues Citi Research analyst Itay Michaeli lowered his estimate on Tesla to reflect disappointing electric vehicle company’s first quarter delivery results. The analyst maintained his Neutral rating on the stock, but cut his price target by $16 to $180. This implies that shares could rise 3.1% over the next year. Tesla shares have fallen about 29.7% this year as the company has struggled with growing Chinese competition and rising sales even after lowering prices. “Given NT Tesla demand headwinds (in our view related to product age and saturation), we still see more downside than upside compared to our NT estimates,” Michaeli wrote in a note Thursday. “Our LT estimates have also been reduced, although we are making no changes to next-generation EV assumptions for now.” Tesla CEO Elon Musk announced last week that he would reveal a new robotaxi product in August, which the analyst said could be a positive move if the company held an event to introduce the robotaxi “along with a roadmap more convincing implementation”. — Pia Singh 5.50am: Morgan Stanley reiterates overweight rating, raises price target on Netflix Netflix could be in a strong period of long-term growth, according to Morgan Stanley. Analyst Benjamin Swinburne reiterated his overweight rating on the streaming stock and raised his price target from $100 to $700, which suggests Netflix shares could rise 11.3%. The stock has gained about 27% this year. “Netflix’s track record includes moving from DVD to streaming, expanding the world’s largest studio, and successfully monetizing password sharing. This track record, combined with new calling options (ads, games, sports from alive) and an EPS CAGR above 25%, supports a premium multiple,” Swinburne wrote in a note on Friday. The analyst projected a compound annual growth rate of 25% between 2024 and 2028 and 30% for the bull case, given the company’s revenue growth and size. Content from outside the United States, original programming and a large library of content with broad engagement could be some of Netflix’s underappreciated competitive advantages, he said. — Pia Singh 5.50am: Wolfe Research Upgrades Mobileye Global According to Wolfe Research, investors will need to buy Mobileye Global after a sharp decline in early 2024. Analyst Shreyas Patil upgraded the autonomous vehicle technology company to outperform versus performance of its peers. Its $41 price target implies an upside of 30% over the next 12 months. Shares struggled in 2024, losing 27.5%. However, Patil believes the risks plaguing the stock earlier this year could be driving Mobileye. MBLY YTD mountain MBLY year-to-date “The biggest debate at this point seems to be over Mobileye’s competitive position, particularly for its ‘hands-free’ supervision system ($1000-$2000 [average sales price];50% [gross margin]) and “hands-free/eyes-free” driver ($3,000-$6,000 ASP; 50% GM),” Patil said in a note. “Simply put, we don’t see a rival that can match MBLY’s capabilities in terms of cost, performance, and scalability, 3 key factors needed to support large-scale adoption,” he said. “And we are increasingly convinced that this will become evident over the next 6-12 months, driven by growing new commercial recognition from of high-volume OEMs.” — Fred Imbert